RxDoctor Payments Data

Mirza Beg, MD

Neurology · South Daytona, FLNPI 1225064322

Payments from drug & device makers

$15,295in general payments, 2019–2025

Across 876 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Livanova USA, Inc.$1K
  • Pfizer$1K
  • Novartis$941
  • Sanofi$837
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$725
  • plus $9K from 54 others

What the payments were for

  • Travel & lodging$3822%
  • Food & beverage$14,83697%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)173$2,138
Livanova USA, Inc.23$1,073
Pfizer59$1,012
Novartis56$941
Sanofi45$837
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC61$725
Teva Pharmaceuticals USA, Inc.32$614
Supernus Pharmaceuticals, Inc.60$603
UCB, Inc.19$565
Collegium Pharmaceutical, Inc.29$527
Biohaven Pharmaceuticals, Inc.26$427
Neurelis, Inc.24$415
Amgen(2 entities)17$401
Biogen20$395
Biohaven Pharmaceutical Holding Company Ltd.22$381
Takeda Pharmaceuticals U.S.A., Inc.14$359
Tanabe Pharma America, Inc.16$306
SK Life Science, Inc.10$275
Johnson & Johnson9$255
Acadia Pharmaceuticals Inc8$233
Corium, LLC11$229
Scilex Pharmaceuticals Inc.12$215
Impel Pharmaceuticals Inc.17$211
Avanir Pharmaceuticals, Inc.10$206
Greenwich Biosciences, Inc.9$167
Sunovion Pharmaceuticals Inc.7$156
Zyla Life Sciences, Inc.10$146
Lilly USA, LLC7$136
Argenx US, Inc.5$102
AstraZeneca6$98
Upsher-smith Laboratories LLC3$77
Harmony Biosciences LLC3$67
CSL Behring3$67
Indivior Inc.3$63
GE HealthCare2$55
Biodelivery Sciences International, Inc.3$55
Boston Scientific3$53
Otsuka America Pharmaceutical, Inc.3$51
Merck3$49
Bristol Myers Squibb3$45
Jazz Pharmaceuticals Inc.2$44
Acorda Therapeutics, Inc2$42
Abbott2$39
Si-bone, Inc.1$36
Arbor Pharmaceuticals, Inc.3$36
Bausch Health US, LLC2$35
Merz North America, Inc.3$34
Nevro Corp.1$29
EMD Serono, Inc.1$28
Alnylam Pharmaceuticals Inc.1$28
Neurocrine Biosciences, Inc.1$25
Pacira Pharmaceuticals Incorporated1$22
Amneal Pharmaceuticals LLC1$19
SPR Therapeutics, Inc1$19
Grifols USA, LLC1$19
Eisai Inc.1$19
Mallinckrodt Hospital Products Inc.1$18
Orthogenrx Inc.1$18
Redhill Biopharma Inc.1$18
Hikma Pharmaceuticals USA1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,295 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$391,919
Medicare patients
297
Services billed
4,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab27$266,275
Xtampza ErOxycodone Myristate187$157,263
UbrelvyUbrogepant77$118,726
RebifInterferon Beta-1a/Albumin12$118,712
OxycontinOxycodone Hcl130$101,179
VumerityDiroximel Fumarate11$89,569
Nurtec OdtRimegepant Sulfate35$68,003
QuliptaAtogepant63$64,215
RelistorMethylnaltrexone Bromide22$53,478
PercocetOxycodone Hcl/Acetaminophen11$49,623
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,189$42,701
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen951$38,591
Aimovig AutoinjectorErenumab-Aooe17$27,496
NuedextaDextromethorphan Hbr/Quinidine12$21,677
MovantikNaloxegol Oxalate45$20,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,138$182,940140 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$527$171,968206 claims
EMD Serono, Inc.Rebif$28$118,71212 claims
BiogenVumerity$395$89,56911 claims
PfizerNurtec Odt$1,012$68,00335 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$725$53,47822 claims
Avanir Pharmaceuticals, Inc.Nuedexta$206$21,67712 claims
Redhill Biopharma Inc.Movantik$18$20,23645 claims
UCB, Inc.Briviact$565$18,01313 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate$17$15,165202 claims
SK Life Science, Inc.Xcopri$275$11,64012 claims
MerckBelsomra$49$11,36426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in South Daytona

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →